Vaccine News and Research

Latest Vaccine News and Research

Scientists discover new cell type in the immune system

A team of Australian scientists has discovered a new type of cell in the immune system. The new cell type, a kind of white blood cell, belongs to a family of T-cells that play a critical role in protection against infectious disease.

16 Jun 2011

Inviragen commences INV21 Phase 1 trial against Hand, Foot and Mouth Disease

Inviragen announced today the initiation of the first clinical trial of the Company's proprietary Hand, Foot and Mouth Disease (HFMD) investigational vaccine, INV21, a highly purified virus particle preparation designed to protect against HFMD caused by enterovirus 71.

16 Jun 2011

Bristol-Myers Squibb receives FDA approval for Nulojix to prevent organ rejection after kidney transplant

The U.S. Food and Drug Administration today approved Nulojix to prevent acute rejection in adult patients who have had a kidney transplant. The drug is approved for use with other immunosuppressants -- specifically basiliximab, mycophenolate mofetil, and corticosteroids.

16 Jun 2011

Galectin strengthens cancer drug patent portfolio in Europe

Galectin Therapeutics Inc. today announced that the European Patent Office has granted the Company a new patent, No. 02731178.6, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer".

15 Jun 2011

GlycoVaxyn's Second Annual Science Day to highlight challenges of vaccine industry

GlycoVaxyn AG, a leader in the development of conjugate vaccines, today announced that it will host its Second Annual Science Day to discuss challenges and opportunities in vaccine development on June 16-17, 2011, in Cannes, France.

15 Jun 2011

OncoSec Medical third quarter net loss increases to $491,000

OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, today reported financial results for the quarter ended April 30, 2011.

15 Jun 2011

Editorial, opinion pieces respond to GAVI pledging conference

Editorials and opinion pieces are responding to the GAVI Alliance pledging conference, which raised $4.3 billion for childhood vaccinations.

15 Jun 2011

Novartis Bexsero pivotal study data on meningococcal serogroup B presented at ESPID

New data from a pivotal study in more than 1,800 infants show that Novartis candidate vaccine Bexsero induces a robust immune response to meningococcal serogroup B when given alone or when co-administered with other routine vaccines.

15 Jun 2011

immatics initiates IMA901 Phase III trial in renal cell carcinoma

igoommatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma.

15 Jun 2011

Meningitis vaccine showing success in West Africa

The New York Times reports on the success of a new meningococcal vaccine in West Africa, where very few cases of the disease have been detected in countries that use MenAfriVac, which costs 50 cents per dose.

15 Jun 2011

Large donations help GAVI raise $4.3B, exceeding goal

"Large donations from the U.K., Norway and the Bill & Melinda Gates Foundation helped a global vaccine charity raise $4.3 billion at a summit Monday, exceeding its targets and allowing it to carry out all its immunization plans through 2015," the Wall Street Journal reports.

15 Jun 2011

GSK, Arecor enter license agreement to develop advanced formulations of vaccines

Arecor and GSK have entered into a license agreement to develop advanced formulations of vaccines combining Arecor's unique formulation technologies with GSK's proprietary vaccines.

15 Jun 2011

Universal influenza vaccination may reduce health care costs in the U.S.

Implementing a recommendation that all Americans be vaccinated against influenza may dramatically reduce health care costs and the number of people infected with seasonal influenza in the United States.

14 Jun 2011

U.K., U.S., Australia, Gates Foundation promise funds to GAVI Alliance at pledging conference

At a pledging conference for the GAVI Alliance in London on Monday, Bill Gates, co-chair of the Bill & Melinda Gates Foundation and Microsoft founder, announced his foundation will provide an additional $1 billion in funding for the organization over the next five years, while Australian Foreign Minister Kevin Rudd said his country will provide $210 million over the next three years, Reuters reports.

14 Jun 2011

Scientists discover new elements of blood clot-formation process

Scripps Research Institute scientists have discovered new elements of the blood clot-formation process. The findings could lead to better drugs for preventing heart attacks and other clot-related conditions.

14 Jun 2011

Dengue virus circulating between monkeys, mosquitoes could emerge to cause human outbreaks

More than a thousand years ago, somewhere in Southeast Asia, a fateful meeting occurred between a mosquito-borne virus that infected mainly monkeys and a large, susceptible group of humans.

14 Jun 2011

Dengue vaccine could be available in four years

A vaccine against the mosquito-borne infection dengue, the first to reach the final stage of clinical testing, "has seen 'very promising' results in Thailand, a specialist involved in the tests said on Friday," Reuters reports.

14 Jun 2011

Billions committed for children’s vaccines

British Prime Minister David Cameron has pledged £814m to help vaccinate children around the world against preventable diseases like pneumonia. He made the announcement at a summit in London where countries are being asked to give an extra £2.3bn ($3.7bn) by 2015 for child vaccines. He said, “Three children die every minute from pneumonia alone. Waiting is not the right thing to do and I don't think that 0.7 per cent of our gross national income is too high a price to pay for saving lives.”

13 Jun 2011

Nose spray vaccine for type 1 diabetes could be a reality soon

Melbourne researchers are nearing the development of a vaccine for type 1 diabetes, after showing that a nasal spray can stop the body's immune system from attacking insulin-producing cells.

13 Jun 2011

Study reveals positive impact of Soliris on long-term outcomes in PNH patients

Alexion Pharmaceuticals, Inc. today announced the presentation of research that provides further insight into the clinical consequences of paroxysmal nocturnal hemoglobinuria (PNH), and positive impact of Soliris® (eculizumab) therapy on long-term outcomes.

13 Jun 2011